Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Identifieur interne : 003468 ( Istex/Corpus ); précédent : 003467; suivant : 003469Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
Auteurs : Penelope Hogarth ; Luca Lovrecic ; Dimitri KraincSource :
- Movement Disorders [ 0885-3185 ] ; 2007-10-15.
English descriptors
Abstract
Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21632
Links to Exploration step
ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title><author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</mods:affiliation></affiliation></author><author><name sortKey="Lovrecic, Luca" sort="Lovrecic, Luca" uniqKey="Lovrecic L" first="Luca" last="Lovrecic">Luca Lovrecic</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Krainc, Dimitri" sort="Krainc, Dimitri" uniqKey="Krainc D" first="Dimitri" last="Krainc">Dimitri Krainc</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21632</idno><idno type="url">https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003468</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title><author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</mods:affiliation></affiliation></author><author><name sortKey="Lovrecic, Luca" sort="Lovrecic, Luca" uniqKey="Lovrecic L" first="Luca" last="Lovrecic">Luca Lovrecic</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation></affiliation></author><author><name sortKey="Krainc, Dimitri" sort="Krainc, Dimitri" uniqKey="Krainc D" first="Dimitri" last="Krainc">Dimitri Krainc</name><affiliation><mods:affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15">2007-10-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1962">1962</biblScope><biblScope unit="page" to="1964">1964</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">6FF31B34BBC74B3B9081F504D87EED5D30419A26</idno><idno type="DOI">10.1002/mds.21632</idno><idno type="ArticleID">MDS21632</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>histone deacetylase inhibitor</term><term>sodium phenylbutyrate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Penelope Hogarth MD</name><affiliations><json:string>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</json:string><json:string>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</json:string></affiliations></json:item><json:item><name>Luca Lovrecic MD</name><affiliations><json:string>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</json:string></affiliations></json:item><json:item><name>Dimitri Krainc MD, PhD</name><affiliations><json:string>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Huntington's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>histone deacetylase inhibitor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>sodium phenylbutyrate</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>3.281</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>822</abstractCharCount><pdfWordCount>1925</pdfWordCount><pdfCharCount>12700</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>113</abstractWordCount></qualityIndicators><title>Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>3</total><last>1964</last><first>1962</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21632</json:string></doi><id>6FF31B34BBC74B3B9081F504D87EED5D30419A26</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><notesStmt><note>PHS - No. 5 M01 RR000334;</note><note>HighQ Foundation</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title><author><persName><forename type="first">Penelope</forename><surname>Hogarth</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Oregon Health & Science University, 3181 SW Sam Jackson Park Road, OP‐32, Portland, OR 97239‐3098</p></note><affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</affiliation><affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</affiliation></author><author><persName><forename type="first">Luca</forename><surname>Lovrecic</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</affiliation></author><author><persName><forename type="first">Dimitri</forename><surname>Krainc</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-10-15"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1962">1962</biblScope><biblScope unit="page" to="1964">1964</biblScope></imprint></monogr><idno type="istex">6FF31B34BBC74B3B9081F504D87EED5D30419A26</idno><idno type="DOI">10.1002/mds.21632</idno><idno type="ArticleID">MDS21632</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Huntington's disease</term></item><item><term>histone deacetylase inhibitor</term></item><item><term>sodium phenylbutyrate</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-02-26">Received</change><change when="2007-05-22">Registration</change><change when="2007-10-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/6FF31B34BBC74B3B9081F504D87EED5D30419A26/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v22:13</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2007-10-15">15 October 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="200" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21632</doi><idGroup><id type="unit" value="MDS21632"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-02-26"></event><event type="manuscriptRevised" date="2007-05-12"></event><event type="manuscriptAccepted" date="2007-05-22"></event><event type="firstOnline" date="2007-08-13"></event><event type="publishedOnlineFinalForm" date="2007-10-26"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2007-08-13"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1962</numbering><numbering type="pageLast">1964</numbering></numberingGroup><correspondenceTo>Oregon Health & Science University, 3181 SW Sam Jackson Park Road, OP‐32, Portland, OR 97239‐3098</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21632.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="8"></count><count type="wordTotal" number="1789"></count></countGroup><titleGroup><title type="main" xml:lang="en">Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title><title type="short" xml:lang="en">Sodium Phenylbutyrate in Huntington′s Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Penelope</givenNames><familyName>Hogarth</familyName><degrees>MD</degrees></personName><contactDetails><email>hogarthp@ohsu.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Luca</givenNames><familyName>Lovrecic</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Dimitri</givenNames><familyName>Krainc</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Huntington's disease</keyword><keyword xml:id="kwd2">histone deacetylase inhibitor</keyword><keyword xml:id="kwd3">sodium phenylbutyrate</keyword></keywordGroup><fundingInfo><fundingAgency>PHS</fundingAgency><fundingNumber>5 M01 RR000334</fundingNumber></fundingInfo><fundingInfo><fundingAgency>HighQ Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Sodium Phenylbutyrate in Huntington′s Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Sodium phenylbutyrate in Huntington's disease: A dose‐finding study</title></titleInfo><name type="personal"><namePart type="given">Penelope</namePart><namePart type="family">Hogarth</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA</affiliation><affiliation>Parkinson's Disease Research, Education & Clinical Center, Portland VA Medical Center, Portland, Oregon, USA</affiliation><description>Correspondence: Oregon Health & Science University, 3181 SW Sam Jackson Park Road, OP‐32, Portland, OR 97239‐3098</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Luca</namePart><namePart type="family">Lovrecic</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Dimitri</namePart><namePart type="family">Krainc</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration (MIND), Charlestown, Massachusetts, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-10-15</dateIssued><dateCaptured encoding="w3cdtf">2007-02-26</dateCaptured><dateValid encoding="w3cdtf">2007-05-22</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">8</extent><extent unit="words">1789</extent></physicalDescription><abstract lang="en">Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose‐finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose‐escalation/de‐escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose‐response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well‐tolerated in human HD. © 2007 Movement Disorder Society</abstract><note type="funding">PHS - No. 5 M01 RR000334; </note><note type="funding">HighQ Foundation</note><subject lang="en"><genre>Keywords</genre><topic>Huntington's disease</topic><topic>histone deacetylase inhibitor</topic><topic>sodium phenylbutyrate</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>1962</start><end>1964</end><total>3</total></extent></part></relatedItem><identifier type="istex">6FF31B34BBC74B3B9081F504D87EED5D30419A26</identifier><identifier type="DOI">10.1002/mds.21632</identifier><identifier type="ArticleID">MDS21632</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003468 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003468 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:6FF31B34BBC74B3B9081F504D87EED5D30419A26
|texte= Sodium phenylbutyrate in Huntington's disease: A dose‐finding study
}}
| This area was generated with Dilib version V0.6.23. |  |